Atakan TEKİNALP, Oğuzhan YILDIZ, Cengizhan DOĞAN, Sinan DEMİRCİOĞLU, Mustafa MERTER, Melek KARAKURT ERYILMAZ
Acta Haematologica Oncologica Turcica - 2026;59(1):32-37
Aim: This study aimed to evaluate time to second primary malignancy (SPM) development and associated clinical factors in adults with a PM. Methods: This retrospective study included patients with hematologic malignancies (HM) and a prior history of solid organ malignancy (SOM) who had complete clinical data available. Results: A total of 101 patients were included. Median age was 61 years (26-88). Median time to SPM was 42.9 months overall, longer in the primary hematologic malignancy than primary SOM (54.9 vs. 26.8 months, p=0.018). Patients <60 years had longer time to SPM than those >=60 (66 vs. 21.4 months, p<0.001). Conclusion: Advanced age is the main determinant of SPM development in adult cancer survivors, highlighting the need for closer surveillance in elderly patients.
